Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis

Company Overview

Hansa Biopharma AB (publ) is a Swedish biopharmaceutical company focused on developing enzyme-based immunomodulatory treatments for patients with rare immunological conditions. Its research centers on therapies that selectively modify or remove disease-causing antibodies, with applications in transplantation, autoimmune diseases and other areas involving the immune system.

The company’s primary product is Idefirix (imlifidase), an enzyme that cleaves immunoglobulin G (IgG) antibodies. Idefirix received conditional marketing authorization in the European Union in 2020 for the desensitization of highly sensitized adult kidney transplant patients who are otherwise unlikely to receive a compatible organ. Hansa Biopharma is also evaluating imlifidase and related programs in additional transplant and immune-mediated indications.

Hansa Biopharma was founded in Sweden in 2007 under the name Hansa Medical and adopted its current name in 2017. The company is headquartered in Lund and operates internationally, with activities focused on Europe and other major biopharmaceutical markets. Its shares are listed in Sweden, and its American depositary trading symbol is HNSBF on the over-the-counter market.

Key Stats

• Today's Range: $3.29 to $3.29
• 50-Day Range: $3.29 to $3.70
• 52-Week Range: $2.90 to $3.70
• Volume: N/A
• Average Volume: 7,550 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Hansa Biopharma AB (publ) Stock Analysis - MarketRank™

Hansa Biopharma AB (publ) scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Hansa Biopharma AB (publ) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hansa Biopharma AB (publ) has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hansa Biopharma AB (publ) is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hansa Biopharma AB (publ) is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Hansa Biopharma AB (publ) has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hansa Biopharma AB (publ) has recently increased by 37.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hansa Biopharma AB (publ) does not currently pay a dividend.

Dividend Growth

Hansa Biopharma AB (publ) does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.17

News Sentiment

Hansa Biopharma AB (publ) has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Hansa Biopharma AB (publ) this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hansa Biopharma AB (publ) insiders have not sold or bought any company stock.

Percentage Held by Institutions

Hansa Biopharma AB (publ) has minimal institutional ownership at this time.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:HNSBF
• CIK: N/A
• Web: www.hansabiopharma.com
• Phone: 46 46 16 56 70
• Fax: N/A
• Employees: 125
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A